% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Deng:301722,
author = {M. Y. Deng and S. L. N. Maas and G. Anil and P. Sievers$^*$
and J. Lischalk and E. Zhao and S. Rauh and I. Jessen and T.
Eichkorn and S. Regnery and L. Bauer and T. Held and P.
Hoegen-Sassmannshausen$^*$ and K. Seidensaal and J.
Hörner-Rieber$^*$ and S. M. Pfister$^*$ and A. Wick$^*$ and
W. Wick$^*$ and A. von Deimling$^*$ and K. Herfarth and C.
Jungk and S. M. Krieg and J. Debus$^*$ and F. Sahm$^*$ and
L. König},
title = {{P}ostoperative radiotherapy in subtotally-resected
recurrent {WHO} grade 1 meningiomas with
intermediate-/high-risk molecular profiles.},
journal = {Neuro-Oncology},
volume = {nn},
issn = {1522-8517},
address = {Oxford},
publisher = {Oxford Univ. Press},
reportid = {DKFZ-2025-01114},
pages = {nn},
year = {2025},
note = {#LA:B300# / epub},
abstract = {Meningiomas represent the most common primary intracranial
tumors in adults, with WHO grade 1 typically associated with
favorable outcomes following gross total resection
(GTR).This retrospective study included patients with CNS
WHO grade 1 meningioma and available DNA methylation
profiles (n=210). Clinical tumor characteristics and
treatment course (e.g., surgical resection, extent of
resection, radiotherapy) were evaluated. Integrated Scores
(InS) were calculated based on methylation family using the
DKFZ brain tumor classifier, CNS WHO grading, and
chromosomal losses, categorized as low, intermediate, or
high. Survival analyses employed Kaplan-Meier and Cox
regression methods, with local progression-free survival
defined as primary endpoint.In newly diagnosed cases, GTR
was associated with a $93.0\%$ 3-year progression-free
survival (PFS), compared to $69.3\%$ following subtotal
resection (STR). Stratification by IntS showed that patients
in the IntS-low group had superior outcomes: 3-y PFS of 93.4
after GTR and $77.4\%$ after STR. In contrast, patients with
IntS-intermediate/high profiles showed significantly worse
outcomes, with PFS of $85.9\%$ after GTR and $40.0\%$ after
STR. Following tumor recurrence, particularly those with
IntS-intermediate/high, postoperative radiotherapy (RT)
after STR may improve 3-year PFS to $88.9\%,$ compared to
much lower PFS rates in newly diagnosed cases managed
without adjuvant RT after STR (3-year PFS: $40.0\%).Our$
findings highlight the combined impact of both the extent of
resection (EoR) and molecular risk profile on prognosis in
newly diagnosed cases. While conservative management is
feasible in lower-risk primary cases, recurrent or
higher-risk patients may benefit from early postoperative
RT.},
keywords = {WHO grade 1 meningioma (Other) / extent of resection
(Other) / integrated score (Other) / molecular diagnostics
(Other)},
cin = {B300 / HD01 / E050 / B062 / B320},
ddc = {610},
cid = {I:(DE-He78)B300-20160331 / I:(DE-He78)HD01-20160331 /
I:(DE-He78)E050-20160331 / I:(DE-He78)B062-20160331 /
I:(DE-He78)B320-20160331},
pnm = {312 - Funktionelle und strukturelle Genomforschung
(POF4-312)},
pid = {G:(DE-HGF)POF4-312},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:40424588},
doi = {10.1093/neuonc/noaf125},
url = {https://inrepo02.dkfz.de/record/301722},
}